Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic Drugs Advisory Committee's enthusiasm for sunitinib was tempered by complexities resulting from the pivotal trial's early termination, and the panel urged that everolimus only be used for patients with aggressive disease.

You may also be interested in...



Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.

Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.

Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease

FDA approval of Novartis' everolimus for progressive pancreatic neuroendocrine tumors is in line with the Oncologic Drugs Advisory Committee's recommendations that the drug be reserved for those patients with more serious disease.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel